Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709462 · ClinicalTrials.gov registry record · Phase 1
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT00709462: Completed Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Celldex Therapeutics.
NCT00709462 is a Phase 1 study of Breast Cancer and Colorectal Cancer that has completed, run by Celldex Therapeutics. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00709462, a Phase 1 study of Breast Cancer and Colorectal Cancer, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additional treatments, in combination, thought to enhance the immune response effect. (CDX 1307-01)
Conditions Studied
Interventions
- BIOLOGICAL CDX1307
Study Locations (3)
North Carolina
- Duke University - Durham
- Carolina BioOncology Institute Cancer - Huntersville
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
What the finished NCT00709462 record still lists
NCT00709462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CDX1307 is the first listed.
NCT00709462 reports a single indexed study location in North Carolina, Michigan.
Frequently Asked Questions
What is clinical trial NCT00709462 about?
NCT00709462 is a clinical study titled "A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)". This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additiona...
What is the current status of trial NCT00709462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2004-03. Estimated completion is 2010-06.
What conditions does trial NCT00709462 study?
This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Bladder Cancer.
What interventions are being tested in trial NCT00709462?
The interventions under investigation include: CDX1307 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00709462?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00709462 being conducted?
This trial has 3 study locations across Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00709462's enrollment target sits among peer trials
48 821st of 1224 higher than 394 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia